Print this page
breast
-
A Single-Arm, Open-Label, Multicenter, Phase II Clinical Study to Evaluate the Tolerability, Safety, and Preliminary Efficacy of Intravesical Administration of Herpes Virus T3011 Injection in Participants with BCG-unresponsive High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC).
Protocol: 082504Principal Investigator:
- Vignesh Packiam
Applicable Disease Sites: Urinary Bladder -
A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer.
Protocol: 082509Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Urinary Bladder -
A Phase I Study to Evaluate the Safety of Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab in Patients with Advanced Melanoma.
Protocol: 092302Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO).
Protocol: 092305Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-ZZFX (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma.
Protocol: 102301Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Other Female Genital -
A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial.
Protocol: 102403Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Any Site
Other Female Genital -
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers.
Protocol: 102405Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Corpus Uteri
Ovary -
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR alpha-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Protocol: 102502Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Ovary -
A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6.
Protocol: 102503Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Ovary -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Any Site
Ovary
Prostate -
A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL).
Protocol: 111707Principal Investigator:
- Archana Sharma
Applicable Disease Sites: Lymphoid Leukemia -
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL).
Protocol: 111803Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Any Site -
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL, Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy.
Protocol: 111911Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Any Site -
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
Protocol: 112008Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, not otherwise specified -
A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged < 1 to < 31 Years Old with First Relapse.
Protocol: 112011Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
Protocol: 112106Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Kidney